<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590379</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-05993BA1-02</org_study_id>
    <secondary_id>2017-004405-41</secondary_id>
    <nct_id>NCT03590379</nct_id>
  </id_info>
  <brief_title>Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>TRI-D</acronym>
  <official_title>A Phase II, Multicentre, Randomised, Double-blind, Double-dummy, Active-controlled, 3-way Cross-over Study to Evaluate the Efficacy of CHF 5993 Administered Via Dry Powder Inhaler (DPI) Versus CHF 5993 Via Pressurized Metered Dose Inhaler (pMDI) and CHF 1535 pMDI in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Fixed Combination of Beclomethasone&#xD;
      Dipropionate + Formoterol Fumarate + Glycopyrronium Bromide Administered Via Dry Powder&#xD;
      Inhaler in COPD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12h (Area Under the Curve for Forced Expiratory Volume in 1 second measured serially for 0-12 hours) normalised by time (L) on dosing Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>To demonstrate the non-inferiority between CHF 5993 DPI and CHF 5993 pMDI in terms of FEV1 AUC0-12h normalized by time, in COPD patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 at 24 hours (L) on dosing Day 28.</measure>
    <time_frame>Day 28</time_frame>
    <description>To demonstrate the non-inferiority between CHF 5993 DPI and CHF 5993 pMDI in terms of trough FEV1 at 24h on dosing Day 28 in COPD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose morning FEV1 (L) on Day 28</measure>
    <time_frame>from Baseline to Day 28</time_frame>
    <description>To evaluate the efficacy of CHF 5993 DPI on other lung function parameters and clinical outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1 AUC0-4h normalised by time (L) on Day 28</measure>
    <time_frame>from Baseline to Day 28</time_frame>
    <description>To evaluate the efficacy of CHF 5993 DPI on other lung function parameters and clinical outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1 AUC0-12h normalised by time (L) on Day 1</measure>
    <time_frame>from Baseline to Day 1</time_frame>
    <description>To evaluate the efficacy of CHF 5993 DPI on other lung function parameters and clinical outcome measures.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>CHF 5993 DPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDP/FF/GB DPI 100/6/12,5 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP/FF/GB pMDI 100/6/12,5 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP/FF pMDI 100/6 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 DPI</intervention_name>
    <description>BDP/FF/GB DPI</description>
    <arm_group_label>CHF 5993 DPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF5993 pMDI</intervention_name>
    <description>BDP/FF/GB pMDI</description>
    <arm_group_label>CHF 5993 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 pMDI</intervention_name>
    <description>BDP/FF pMDI</description>
    <arm_group_label>CHF 1535 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo DPI</intervention_name>
    <description>CHF 5993 DPI matched placebo</description>
    <arm_group_label>CHF 1535 pMDI</arm_group_label>
    <arm_group_label>CHF 5993 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pMDI</intervention_name>
    <description>CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)</description>
    <arm_group_label>CHF 5993 DPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults (40 ≤ age ≤ 85 years) with a diagnosis of COPD;&#xD;
&#xD;
          -  Current smokers or ex-smokers;&#xD;
&#xD;
          -  A Post-bronchodilator FEV1 ≥30% and &lt;80% of the predicted normal value and FEV1/FVC&#xD;
             (Forced Vital Capacity) &lt; 0.7;&#xD;
&#xD;
          -  Patients' COPD therapy (stable regimen at least 30 days before screening) with either:&#xD;
&#xD;
               -  Inhaled corticosteroids/long-acting β2-agonist/long-acting muscarinic antagonist&#xD;
                  (free or fixed) combination&#xD;
&#xD;
               -  Inhaled corticosteroids/long-acting β2-agonist (free or fixed) combination&#xD;
&#xD;
               -  Inhaled long-acting β2-agonist/long-acting muscarinic antagonist (free or fixed)&#xD;
                  combination&#xD;
&#xD;
               -  Inhaled long-acting muscarinic antagonist alone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  Diagnosis of asthma;&#xD;
&#xD;
          -  Known respiratory disorders other than COPD;&#xD;
&#xD;
          -  Patients treated for a moderate or severe COPD exacerbation within 6 weeks prior to&#xD;
             screening or during the run-in period;&#xD;
&#xD;
          -  Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic&#xD;
             hypoxemia;&#xD;
&#xD;
          -  Patients who have clinically significant cardiovascular condition;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai-Michael Beeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center Convex EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004405-41/results</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis. 2021 Jan 14;16:79-89. doi: 10.2147/COPD.S291030. eCollection 2021.</citation>
    <PMID>33488071</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.&#xD;
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_description>
    <ipd_access_criteria>Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_access_criteria>
    <ipd_url>https://www.chiesi.com/en/chiesi-clinical-trial-data-request-portal/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

